Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Italy halts AstraZeneca vaccine for under-60s

Published 06/11/2021, 11:33 AM
Updated 06/11/2021, 01:11 PM
© Reuters. FILE PHOTO: A nurse prepares a dose of AstraZeneca coronavirus disease (COVID-19) vaccine in Fasano Italy, April 13, 2021. REUTERS/Alessandro Garofalo/File Photo

© Reuters. FILE PHOTO: A nurse prepares a dose of AstraZeneca coronavirus disease (COVID-19) vaccine in Fasano Italy, April 13, 2021. REUTERS/Alessandro Garofalo/File Photo

By Gavin Jones

ROME (Reuters) -The Italian government said on Friday it was restricting the use of the AstraZeneca (NASDAQ:AZN) COVID-19 vaccine to people over the age of 60, after a teenager who had received the shot died from a rare form of blood clotting.

Camilla Canepa died on Thursday aged 18 after being given the vaccine on May 25, triggering a media and political outcry over the Anglo-Swedish company's shot being used for adults of all ages despite previously-raised medical concerns.

"AstraZeneca will only be used for people over 60," the country's special COVID commissioner Francesco Figliuolo told reporters.

People under the age of 60 who have received a first dose of AstraZeneca should be given a different vaccine for the second dose, the government's chief medical adviser Franco Locatelli said at the same news conference.

"The risk-benefit assessment has changed," Locatelli said, without mentioning the death of Canepa, who suffered from a low platelet count, brain haemorrhage and abdominal blood clots.

AstraZeneca was not immediately available to comment.

Like many European countries, Italy briefly halted AstraZeneca inoculations in March over concerns of rare blood clotting problems, mainly in young people.

It resumed them the following month with the recommendation the product be "preferably" used for people over the age of 60, after the European drug regulator said the benefits of the jab outweighed the risks.

Several other European countries have also stopped giving the AstraZeneca COVID-19 vaccine to people below a certain age, usually ranging from 50 to 65.

However, as Mario Draghi's government sought to ramp up its vaccination drive, some Italian regions launched "open days" where the AstraZeneca shot was administered to people of any age from 18 upwards.

These included young women who are the group considered most at risk of the extremely rare blood clotting disorders.

© Reuters. FILE PHOTO: A nurse prepares a dose of AstraZeneca coronavirus disease (COVID-19) vaccine in Fasano Italy, April 13, 2021. REUTERS/Alessandro Garofalo/File Photo

The inoculation events, often held during evenings and weekends, were partly aimed at preventing AstraZeneca doses going to waste amid widespread reports of older people spurning the product and cancelling their vaccination appointments.

Around 46% of people in Italy have received at least one vaccine dose, while 23% are fully inoculated, figures broadly in line with most other EU countries.

(additional reporting by Angelo Amante; Editing by Kirsten Donovan)

Latest comments

The risk is 0.00001%, the vaccine is very safe and efficient.
Tip of the iceberg for how bad these “vaccines” are for people
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.